The Filing Desk

Metagenomi Therapeutics vs Entrada Therapeutics

Metagenomi Therapeutics MGX · Entrada Therapeutics TRDA · Biotechnology

Entrada Therapeutics reported revenue of $25 million in fiscal 2025, about the same as Metagenomi Therapeutics' $25 million in fiscal 2025. Metagenomi Therapeutics' revenue fell 51.8% in its latest year, and Entrada Therapeutics' fell 87.9%. Metagenomi Therapeutics had an operating margin of -380.9%, against -621.1% at Entrada Therapeutics. Free cash flow was −$89 million at Metagenomi Therapeutics and −$130 million at Entrada Therapeutics.

Side by side

Metagenomi TherapeuticsEntrada Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$25M$25M
Revenue growth−51.8%−87.9%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin−380.9%−621.1%
Net margin−348.5%−565.5%
Free cash flow−$89M−$130M
Free cash flow margin−354.9%−509.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count12.8%6.1%
Last close$0.61$4.64
P/E at the last close——
Insider trades, last 12 monthsbought $23,401, sold $33,075bought $291,124, sold $6.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Metagenomi TherapeuticsEntrada Therapeutics
Operating margin
Percent of revenue
Metagenomi TherapeuticsEntrada Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Metagenomi TherapeuticsEntrada Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Metagenomi Therapeutics and Entrada Therapeutics pages.